Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients ; volume:42 ; number:1 ; day:14 ; month:11 ; year:2023 ; pages:1-14 ; date:12.2023
Journal of experimental & clinical cancer research ; 42, Heft 1 (14.11.2023), 1-14, 12.2023
- Urheber
-
Wimmer, Kerstin
Sachet, Monika
Ramos, Cristiano
Frantal, Sophie
Birnleitner, Hanna
Brostjan, Christine
Exner, Ruth
Filipits, Martin
Bago-Horvath, Zsuzsanna
Rudas, Margaretha
Bartsch, Rupert
Gnant, Michael
Singer, Christian F.
Balic, Marija
Egle, Daniel
Oehler, Rudolf
Fitzal, Florian
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13046-023-02876-x
- URN
-
urn:nbn:de:101:1-2024013015201835508514
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wimmer, Kerstin
- Sachet, Monika
- Ramos, Cristiano
- Frantal, Sophie
- Birnleitner, Hanna
- Brostjan, Christine
- Exner, Ruth
- Filipits, Martin
- Bago-Horvath, Zsuzsanna
- Rudas, Margaretha
- Bartsch, Rupert
- Gnant, Michael
- Singer, Christian F.
- Balic, Marija
- Egle, Daniel
- Oehler, Rudolf
- Fitzal, Florian
- SpringerLink (Online service)
Ähnliche Objekte (12)
Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients
Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
Epirubicin and cyclophosphamide-induced hematologic changes and recommendation for monitoring in clinical practice
Cyclophosphamide and epirubicin induce high apoptosis in microglia cells while epirubicin provokes DNA damage and microglial activation at sub-lethal concentrations
Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients
QT-Intervall-Verlängerung bei Patientinnen mit Mammakarzinom nach Therapie mit Epirubicin, Cyclophosphamid und Docetaxel und Beurteilung der Interobservervariabilität
Epirubicin-induced Kounis syndrome
Intravenous cyclophosphamide therapy for patients with severe ocular inflammatory diseases who failed other immunomodulatory therapies
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study
Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial
Predictors of primary breast cancers responsiveness to preoperative Epirubicin/Cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures
Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients
Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
Epirubicin and cyclophosphamide-induced hematologic changes and recommendation for monitoring in clinical practice
Cyclophosphamide and epirubicin induce high apoptosis in microglia cells while epirubicin provokes DNA damage and microglial activation at sub-lethal concentrations
Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients
QT-Intervall-Verlängerung bei Patientinnen mit Mammakarzinom nach Therapie mit Epirubicin, Cyclophosphamid und Docetaxel und Beurteilung der Interobservervariabilität
Epirubicin-induced Kounis syndrome
Intravenous cyclophosphamide therapy for patients with severe ocular inflammatory diseases who failed other immunomodulatory therapies
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study
Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial
Predictors of primary breast cancers responsiveness to preoperative Epirubicin/Cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures
Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients
Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
Epirubicin and cyclophosphamide-induced hematologic changes and recommendation for monitoring in clinical practice
Cyclophosphamide and epirubicin induce high apoptosis in microglia cells while epirubicin provokes DNA damage and microglial activation at sub-lethal concentrations
Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients
QT-Intervall-Verlängerung bei Patientinnen mit Mammakarzinom nach Therapie mit Epirubicin, Cyclophosphamid und Docetaxel und Beurteilung der Interobservervariabilität
Epirubicin-induced Kounis syndrome
Intravenous cyclophosphamide therapy for patients with severe ocular inflammatory diseases who failed other immunomodulatory therapies
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study
Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial